ALS Finding a Cure
2
10M
2
- Areas of investment
Summary
The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Stamford.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2016. The fund is constantly included in less than 2 investment rounds annually.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the ALS Finding a Cure, startups are often financed by Techammer, OS Fund, NanoDimension. The meaningful sponsors for the fund in investment in the same round are Techammer, OS Fund, NanoDimension. In the next rounds fund is usually obtained by ALS Investment Fund, Starlight Ventures, SciFi VC.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Emulate
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Investments by industry
- Biotechnology (2)
- Medical (2)
- Commercial (1)
- Health Care (1)
- Life Science (1) Show 2 more
- Investments by region
-
- United States (2)
- Peak activity year
- 2016
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals | 20 Jul 2016 | Biotechnology, Medical, Neuroscience, Pharmaceutical | Seed | 3M | United States, Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.